Zoe Harris – How do you personalise care for dementia patients?
Release Date: 06/23/2020
How do you develop a T-cell therapy to prevent organ transplant rejection?
Beyond The Molecule
Emma Morris and Iain McGill uncover the fascinating story behind Quell Therapeutics, revealing how a team of 6 top scientists came together to develop a pioneering cell and gene therapy that harnesses the body's immune response to prevent life-threatening organ transplant rejection. In this episode, we cover the cutting-edge science, top trends in precision medicine, and what it takes to build a successful biotech in just 2 years.
info_outline
How do you empower patients of color to take part in clinical trials?
Beyond The Molecule
Karen Petersen shares her inspiring story, mapping her journey from cancer survivor to founder of Karen's Club – a not-for-profit designed to support patients of color considering taking part in oncology clinical trials. She explores challenging topics, including building trust in marginalized communities, to reveal how life science companies can break down barriers to help patients participate in life-saving research.
info_outline
How does Medical Alley build and scale healthcare start-ups?
Beyond The Molecule
Building a successful healthcare start-up takes tremendous amounts of time, knowledge, and funding – and new ventures face roadblocks at every turn. So, how do entrepreneurs navigate this incredibly complex market? Frank Jaskulke, Vice President of Intelligence at The Medical Alley Association, shares the lessons he’s learned and reveals how he is helping start-ups to scale, pivot, and build the social capital essential for winning in business and staying at the forefront of innovation.
info_outline
How does Roche and Genentech drive inclusive research globally?
Beyond The Molecule
Approximately 80% of clinical research and genomic studies consist of data from Caucasian participants. Roche and Gene tech are determined to change that. Nicole Riche, Global Head of Health Equity and Population Science, reveals how her team developed a pioneering global strategy to address healthcare disparities across the entire product lifecycle to ensure the promise of personalized health care becomes a reality for all patients.
info_outline
How do you use AI to diagnose rare diseases?
Beyond The Molecule
The rare disease diagnostic odyssey lasts on average 4.5 years. But what would happen if a novel innovation could diagnose a person with a rare disease instantaneously? Vanessa Lemarié, Director of Life Sciences Business Development and Program Owner of the Rare Disease Initiative at Ada Health, explains how the company is leveraging their ground-breaking medical AI technology to simplify diagnostic pathways and make the rare disease diagnostic odyssey a thing of the past.
info_outline
How do you ensure clinical trial access for all?
Beyond The Molecule
The virtual clinical trial space exploded during the COVID-19 pandemic. We chat to Medable founder & CEO Michelle Longmire to explore how her global platform empowers clinicians to develop patient-centric research strategies. We uncover how she's coped with the rapid success that saw the company's revenue grow by more than 500% in 2020, & what the future holds for decentralized clinical trials & digital endpoints.
info_outline
We’re back for season 2
Beyond The Molecule
James Atherton is back for season 2 of Beyond the Molecule, a podcast by Fishawack Health, and this time he’s accompanied by brand new co-host Ross Toohey. This season they uncover new never-before-told stories of healthcare innovation and chat to the CEOs, life science pioneers, and healthcare tech entrepreneurs transforming patient outcomes with cutting-edge solutions.
info_outline
How do you launch a therapy for an ultra-rare disease?
Beyond The Molecule
In this special bonus episode, we deep dive into rare disease and reveal not one but two perspectives from specialists in this area. First Leena Delal, Vice President, US Brand Lead at Alnylam tells the story behind ONPATTRO – a therapy that astounded doctors and patients with its ability to reverse the debilitating nerve damage caused by ultra-rare disease hATTR amyloidosis. Then, our Creative Director Kristin Morris, reveals what she learned in 11 years working solely in rare disease. She covers the changing landscape, how COVID-19 is impacting the patients, and her tips for ensuring...
info_outline
How do you find and fund innovation?
Beyond The Molecule
Have you ever wondered how venture capitalists know which healthcare tech to invest in? Physician turned VC Sunny Kumar reveals how he differentiates between hype and true innovation, why he’s passionate about artificial intelligence and informatics, and what the future looks like for the healthcare tech industry in the aftermath of COVID-19.
info_outline
Jill Hopkins - How do you save people’s sight?
Beyond The Molecule
Jill Hopkins has dedicated her life to restoring people’s vision. In this episode she talks about what it’s like to fight blindness, a game-changing innovation in ophthalmology, and how Roche-Genentech keeps innovating in the wake of COVID-19.
info_outlineWhen her husband battled dementia and lost the ability to communicate, Zoe saw first-hand how the care team’s failure to understand his needs negatively impacted his outcomes. So, she took matters into her own hands. She developed a tool to personalise his care and now her solution – MyCareMatters – is used by care staff and hospitals across the UK.